The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica’s in vitro study on SARS-CoV-2
On July 20 Enzymatica announced the preliminary results from the in vitro study, showing that the mouth spray ColdZyme® deactivates SARS-CoV-2, the virus causing the COVID-19 pandemic. The results of the study, which also includes the common cold virus HCoV-229E, have now been published in the Journal of Medical Virology in the article “Inactivation of SARS-CoV-2 and HCoV-229E in vitro by a medical device mouth spray”.The conclusion of the study is that the mouth spray ColdZyme can inactivate the respiratory coronaviruses SARS‐CoV‐2 and HCoV‐229E in vitro, by 98.3% and 99.9% respectively.